Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Darrington, D. L.
Right arrow Articles by Tarantolo, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Darrington, D. L.
Right arrow Articles by Tarantolo, S. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 12, 2527-2534, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

DL Darrington, JM Vose, JR Anderson, PJ Bierman, MR Bishop, WC Chan, ME Morris, EC Reed, WG Sanger and SR Tarantolo
Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330.

PURPOSE: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). PATIENTS AND METHODS: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a- cohort study undertaken. RESULTS: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total- body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. CONCLUSION: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age > or = 40 years at the time of transplant and who received TBI are at greatest risk.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. Chakraborty, C.-L. Sun, L. Francisco, M. Sabado, L. Li, K. L. Chang, S. Forman, S. Bhatia, and R. Bhatia
Accelerated Telomere Shortening Precedes Development of Therapy-Related Myelodysplasia or Acute Myelogenous Leukemia After Autologous Transplantation for Lymphoma
J. Clin. Oncol., February 10, 2009; 27(5): 791 - 798.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M Devetten and J. Armitage
Hematopoietic cell transplantation: progress and obstacles
Ann. Onc., September 1, 2007; 18(9): 1450 - 1456.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman
Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up
J. Clin. Oncol., June 20, 2007; 25(18): 2554 - 2559.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kalaycio, L. Rybicki, B. Pohlman, R. Sobecks, S. Andresen, E. Kuczkowski, and B. Bolwell
Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia
J. Clin. Oncol., August 1, 2006; 24(22): 3604 - 3610.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Brown and A. S. Freedman
In Reply:
J. Clin. Oncol., November 1, 2005; 23(31): 8121 - 8122.
[Full Text] [PDF]

Home page
 JCOHome page
D. L. Forrest, D. E. Hogge, T. J. Nevill, S. H. Nantel, M. J. Barnett, J. D. Shepherd, H. J. Sutherland, C. L. Toze, C. A. Smith, J. C. Lavoie, et al.
High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation
J. Clin. Oncol., November 1, 2005; 23(31): 7994 - 8002.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Bhatia, K. Van Heijzen, A. Palmer, A. Komiya, M. L. Slovak, K. L. Chang, H. Fung, A. Krishnan, A. Molina, A. Nademanee, et al.
Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma
J. Clin. Oncol., September 20, 2005; 23(27): 6699 - 6711.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Bhatia, L. L. Robison, L. Francisco, A. Carter, Y. Liu, M. Grant, K. S. Baker, H. Fung, J. G. Gurney, P. B. McGlave, et al.
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study
Blood, June 1, 2005; 105(11): 4215 - 4222.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Brown, H. Yeckes, J. W. Friedberg, D. Neuberg, H. Kim, L. M. Nadler, and A. S. Freedman
Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma
J. Clin. Oncol., April 1, 2005; 23(10): 2208 - 2214.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Vose, P. J. Bierman, C. Enke, J. Hankins, G. Bociek, J. C. Lynch, and J. O. Armitage
Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma
J. Clin. Oncol., January 20, 2005; 23(3): 461 - 467.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
A. T. Look
Molecular Pathogenesis of MDS
Hematology, January 1, 2005; 2005(1): 156 - 160.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. W. Milligan, S. Fernandes, R. Dasgupta, F. E. Davies, E. Matutes, C. D. Fegan, C. McConkey, J. A. Child, D. Cunningham, G. J. Morgan, et al.
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses
Blood, January 1, 2005; 105(1): 397 - 404.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Lenz, M. Dreyling, E. Schiegnitz, T. Haferlach, J. Hasford, M. Unterhalt, and W. Hiddemann
Moderate Increase of Secondary Hematologic Malignancies After Myeloablative Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group
J. Clin. Oncol., December 15, 2004; 22(24): 4926 - 4933.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Czyz, R. Dziadziuszko, W. Knopinska-Postuszuy, A. Hellmann, L. Kachel, J. Holowiecki, J. Gozdzik, J. Hansz, A. Avigdor, A. Nagler, et al.
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients
Ann. Onc., August 1, 2004; 15(8): 1222 - 1230.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Andre, N. Mounier, X. Leleu, A. Sonet, P. Brice, M. Henry-Amar, H. Tilly, B. Coiffier, A. Bosly, P. Morel, et al.
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
Blood, February 15, 2004; 103(4): 1222 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. A. Lister
High-Dose Therapy for Follicular Lymphoma Revisited: Not If, but When?
J. Clin. Oncol., November 1, 2003; 21(21): 3894 - 3896.
[Full Text] [PDF]

Home page
 JCOHome page
H. C. Schouten, W. Qian, S. Kvaloy, A. Porcellini, H. Hagberg, H. E. Johnsen, J. K. Doorduijn, M. R. Sydes, and G. Kvalheim
High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin's Lymphoma: Results From the Randomized European CUP Trial
J. Clin. Oncol., November 1, 2003; 21(21): 3918 - 3927.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. M. Smith, M. M. Le Beau, D. Huo, T. Karrison, R. M. Sobecks, J. Anastasi, J. W. Vardiman, J. D. Rowley, and R. A. Larson
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
Blood, July 1, 2003; 102(1): 43 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. Kroger, A. R. Zander, G. Martinelli, P. Ferrante, J. M. Moraleda, G. A. Da Prada, T. Demirer, G. Socie, and G. Rosti
Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation
Ann. Onc., April 1, 2003; 14(4): 554 - 558.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. O. Armitage, P. P. Carbone, J. M. Connors, A. Levine, J. M. Bennett, and S. Kroll
Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients
J. Clin. Oncol., March 1, 2003; 21(5): 897 - 906.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Metayer, R. E. Curtis, J. Vose, K. A. Sobocinski, M. M. Horowitz, S. Bhatia, J. W. Fay, C. O. Freytes, S. C. Goldstein, R. H. Herzig, et al.
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
Blood, March 1, 2003; 101(5): 2015 - 2023.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny
Intensive therapies in follicular non-Hodgkin lymphomas
Blood, July 30, 2002; 100(4): 1141 - 1152.
[Full Text] [PDF]

Home page
 The OncologistHome page
P. McLaughlin
Progress and Promise in the Treatment of Indolent Lymphomas
Oncologist, June 1, 2002; 7(3): 217 - 225.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Hosing, M. Munsell, S. Yazji, B. Andersson, D. Couriel, M. de Lima, M. Donato, J. Gajewski, S. Giralt, M. Korbling, et al.
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma
Ann. Onc., March 1, 2002; 13(3): 450 - 459.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I. Barista, F. Cabanillas, J. E. Romaguera, I. F. Khouri, Y. Yang, T. L. Smith, S. S. Strom, L. J. Medeiros, and F. B. Hagemeister
Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?
Ann. Onc., February 20, 2002; 13(2): 318 - 322.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. R. Wingard, G. B. Vogelsang, and H. J. Deeg
Stem Cell Transplantation: Supportive Care and Long-Term Complications
Hematology, January 1, 2002; 2002(1): 422 - 444.
[Abstract] [Full Text]

Home page
 JCOHome page
H. C. Fung, A. P. Nademanee, S. Bhatia, S. J. Forman, A. Sureda, and E. Conde
Is There an Association Between Total-Body Irradiation and Secondary Acute Myelogenous Leukemia/Myelodysplastic Syndrome in Patients With Relapsed/Refractory Hodgkin's Disease Treated With Autologous Stem-Cell Transplantation?
J. Clin. Oncol., August 1, 2001; 19(15): 3585 - 3588.
[Full Text]

Home page
 JCOHome page
D. M. Lillington, I. N.M. Micallef, E. Carpenter, M. J. Neat, J. A.L. Amess, J. Matthews, N. J. Foot, B. D. Young, T. A. Lister, and A. Z.S. Rohatiner
Detection of Chromosome Abnormalities Pre-High-Dose Treatment in Patients Developing Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After Treatment for Non-Hodgkin's Lymphoma
J. Clin. Oncol., May 1, 2001; 19(9): 2472 - 2481.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. van Besien, M. Kelta, and P. Bahaguna
Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management
J. Clin. Oncol., March 15, 2001; 19(6): 1855 - 1864.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Sureda, R. Arranz, A. Iriondo, E. Carreras, J.J. Lahuerta, J. Garcia-Conde, I. Jarque, M.D. Caballero, C. Ferra, A. Lopez, et al.
Autologous Stem-Cell Transplantation for Hodgkin's Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group
J. Clin. Oncol., March 1, 2001; 19(5): 1395 - 1404.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Bhatia, A. D. Louie, R. Bhatia, M. R. O'Donnell, H. Fung, A. Kashyap, A. Krishnan, A. Molina, A. Nademanee, J. C. Niland, et al.
Solid Cancers After Bone Marrow Transplantation
J. Clin. Oncol., January 15, 2001; 19(2): 464 - 471.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. J. Horning, R. S. Negrin, R. T. Hoppe, S. A. Rosenberg, N. J. Chao, G. D. Long, B. W. Brown, and K. G. Blume
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial
Blood, January 15, 2001; 97(2): 404 - 409.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. C. Kluin-Nelemans, V. Zagonel, A. Anastasopoulou, D. Bron, K. J. Roozendaal, E. M. Noordijk, H. Musson, I. Teodorovic, B. Maes, A. Carbone, et al.
Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin's Lymphoma: Randomized Phase III EORTC Study
J Natl Cancer Inst, January 3, 2001; 93(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. W. Press, J. F. Eary, T. Gooley, A. K. Gopal, S. Liu, J. G. Rajendran, D. G. Maloney, S. Petersdorf, S. A. Bush, L. D. Durack, et al.
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
Blood, November 1, 2000; 96(9): 2934 - 2942.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Mounier, C. Gisselbrecht, J. W. Friedberg, D. Neuberg, and A. S. Freedman
Myelodysplasia After Autotransplantation
J. Clin. Oncol., October 19, 2000; 18(19): 3446 - 3447.
[Full Text] [PDF]

Home page
 BloodHome page
J. Pedersen-Bjergaard, M. K. Andersen, and D. H. Christiansen
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
Blood, June 1, 2000; 95(11): 3273 - 3279.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. O. Armitage
Myelodysplasia and Acute Leukemia After Autologous Bone Marrow Transplantation
J. Clin. Oncol., March 1, 2000; 18(5): 945 - 945.
[Full Text] [PDF]

Home page
 JCOHome page
I. N. M. Micallef, D. M. Lillington, J. Apostolidis, J. A. L. Amess, M. Neat, J. Matthews, T. Clark, J. M. Foran, A. Salam, T. A. Lister, et al.
Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After High-Dose Therapy With Autologous Hematopoietic Progenitor-Cell Support for Lymphoid Malignancies
J. Clin. Oncol., March 1, 2000; 18(5): 947 - 947.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Krishnan, S. Bhatia, M. L. Slovak, D. A. Arber, J. C. Niland, A. Nademanee, H. Fung, R. Bhatia, A. Kashyap, A. Molina, et al.
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors
Blood, March 1, 2000; 95(5): 1588 - 1593.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Apostolidis, R. K. Gupta, D. Grenzelias, P. W. M. Johnson, V. I. Pappa, K. E. Summers, A. Salam, K. Adams, A. J. Norton, J. A. L. Amess, et al.
High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up
J. Clin. Oncol., February 1, 2000; 18(3): 527 - 527.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
F. Cabanillas, S. Horning, M. Kaminski, and R. Champlin
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options
Hematology, January 1, 2000; 2000(1): 166 - 179.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. S. Freedman, D. Neuberg, P. Mauch, R. J. Soiffer, K. C. Anderson, D. C. Fisher, R. Schlossman, E. P. Alyea, T. Takvorian, H. Jallow, et al.
Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma
Blood, November 15, 1999; 94(10): 3325 - 3333.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. W. Friedberg, D. Neuberg, R. M. Stone, E. Alyea, H. Jallow, A. LaCasce, P. M. Mauch, J. G. Gribben, J. Ritz, L. M. Nadler, et al.
Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma
J. Clin. Oncol., October 1, 1999; 17(10): 3128 - 3135.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Aristei and A. Tabilio
Total-Body Irradiation in the Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoproliferative Diseases
Oncologist, October 1, 1999; 4(5): 386 - 397.
[Abstract] [Full Text]

Home page
 BloodHome page
A. C. Aisenberg
Problems in Hodgkin's Disease Management
Blood, February 1, 1999; 93(3): 761 - 779.
[Full Text] [PDF]

Home page
 JCOHome page
J. Apostolidis, J. M. Foran, P.W.M. Johnson, A. Norton, J. Amess, J. Matthews, M. Bradburn, T.A. Lister, and A. Z.S. Rohatiner
Patterns of Outcome Following Recurrence After Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma
J. Clin. Oncol., January 1, 1999; 17(1): 216 - 216.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Andre, M. Henry-Amar, D. Blaise, P. Colombat, J. Fleury, N. Milpied, J.-Y. Cahn, J.-L. Pico, Y. Bastion, M. Kuentz, et al.
Treatment-Related Deaths and Second Cancer Risk After Autologous Stem-Cell Transplantation for Hodgkin's Disease
Blood, September 15, 1998; 92(6): 1933 - 1940.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Mach-Pascual, R. D. Legare, D. Lu, M. Kroon, D. Neuberg, R. Tantravahi, R. M. Stone, A. S. Freedman, L. M. Nadler, J. G. Gribben, et al.
Predictive Value of Clonality Assays in Patients With Non-Hodgkin's Lymphoma Undergoing Autologous Bone Marrow Transplant: A Single Institution Study
Blood, June 15, 1998; 91(12): 4496 - 4503.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. J. Deeg and G. Socie
Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers
Blood, March 15, 1998; 91(6): 1833 - 1844.
[Full Text] [PDF]

Home page
 BloodHome page
A. Nademanee, A. Molina, M. R. O'Donnell, A. Dagis, D. S. Snyder, P. Parker, A. Stein, E. Smith, I. Planas, A. Kashyap, et al.
Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group
Blood, November 15, 1997; 90(10): 3844 - 3852.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. J. Horning, N. J. Chao, R. S. Negrin, R. T. Hoppe, G. D. Long, W. W. Hu, R. M. Wong, B. W. Brown, and K. G. Blume
High-Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplantation for Recurrent or Refractory Hodgkin's Disease: Analysis of the Stanford University Results and Prognostic Indices
Blood, February 1, 1997; 89(3): 801 - 813.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1994 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online